Published on 22/12/2025

Understanding Regional Differences in Clinical Study Start-Up Timelines

Launching a clinical trial globally requires careful planning around regional variations in start-up timelines. Different countries and regulatory agencies follow unique pathways for ethics approvals, regulatory submissions, and site activation. This article provides a practical, comparative guide on start-up timelines across major global regions to help trial professionals plan efficiently and avoid delays.

Table of Contents

Why Start-Up Timelines Vary by Region:

Several factors influence the variability in start-up timelines worldwide:

Different regulatory authority review periods
Independent or centralized ethics committees
Language translation requirements
Contract negotiation timelines
Local import/export or clinical trial insurance regulations

Understanding these nuances is crucial for a global study launch strategy and timeline forecasting.

North America: United States and Canada

United States: Start-up is relatively streamlined but hinges on FDA submissions and IRB reviews.

IND Review by USFDA: 30 days post-submission (for non-exempt studies)
IRB Approval: 4–6 weeks (central IRB is faster than local)
Site Contracts & Budgeting: 2–4 weeks
Total Start-Up Time: 60–90 days

Canada: Requires submission to Health Canada and REB (Research Ethics Board).

Health Canada Review: ~30 days
REB Review: 4–8 weeks
Total Start-Up Time: 90–120 days

European Union (EU): Harmonized But Complex

Since the implementation of EU Clinical Trials Regulation (CTR), regulatory and ethics approvals are centralized, improving harmonization but still facing country-specific interpretation challenges.

Regulatory

Approval via CTIS: 60–90 days

Ethics Review: Simultaneous or post-regulatory in some member states

Contract & Budgeting: Adds 30–60 days depending on institution

Total Start-Up Time: 120–180 days

Start-up timelines in countries like Germany, Spain, and Italy are longer due to layered review systems.

Asia-Pacific: Japan, China, and Australia

Japan (PMDA):

Pre-submission consultation: Mandatory
PMDA Approval: 90–180 days
IRB Approval: ~60 days
Total Start-Up Time: 180–240 days

China (NMPA/SFDA):

Clinical Trial Application: 60–90 working days
IRB Approval: 4–8 weeks
Import License for IMP: Often a cause of delay
Total Start-Up Time: 150–210 days

Australia (TGA):

CTN Scheme: No formal TGA review, sponsor-notified
Ethics Approval: 30–60 days (via HREC)
Faster timelines with single-site ethics review
Total Start-Up Time: 60–90 days

Latin America: Brazil and Mexico

Brazil (ANVISA):

Ethics Review (CEP): 60–90 days
Regulatory Review (CONEP/ANVISA): 90–180 days
Total Start-Up Time: 150–240 days

Mexico:

COFEPRIS Approval: 60–120 days
IRB Review: 4–6 weeks
Total Start-Up Time: 120–180 days

Middle East & Africa

Timelines in this region are often extended due to less digitized systems and limited ethics infrastructure.

South Africa (SAHPRA): 90–120 days regulatory + 30–60 days ethics
Saudi Arabia (SFDA): ~90–120 days total
Typical Total Start-Up: 120–180+ days

Key Factors Impacting Timelines Globally:

Single vs. multiple IRB/EC layers
Regulatory review type (expedited vs full)
Contract negotiation cycles
Drug import/export requirements
Availability of translation and submission support

Using SOPs for document readiness, like those on Pharma SOP templates, can significantly improve timelines.

Using Digital Tools to Accelerate Start-Up:

Modern clinical operations leverage platforms to streamline global start-up:

eTMF systems for document management
Study Start-Up platforms for tracking and escalation
e-submission portals (CTIS, SUGAM, etc.)
Centralized IRBs to reduce review time

Trial professionals must consider digital adaptation when operating across borders.

Best Practices for Managing Global Start-Up:

Map region-specific start-up timelines during feasibility
Build realistic Gantt charts with buffer time for each region
Engage local CROs or consultants with regulatory expertise
Standardize document templates across all sites
Track progress using dashboards and milestone alerts

Conclusion:

Clinical study start-up timelines vary widely across regions due to diverse regulatory landscapes and approval processes. Understanding these differences is key to realistic planning and risk mitigation. By aligning with local regulations, using centralized tools, and implementing SOP-driven workflows, study teams can accelerate activation timelines globally. For further guidance on document readiness and planning, platforms like Stability Studies can be valuable.